The physician-related barriers may include their knowledge of updated guidelines, the experience of insulin therapy, beliefs and attitudes toward insulin and diabetes management, side effects of insulin therapy (e.g., hypoglycemia and weight gain), and finally, perceptions about the patients’ attitudes toward insulin therapy [8-11]. This evidence concerns the gene INS and diabetes mellitus.